Inhaled insulin: Overview of a novel route of insulin administration

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 47-58

  Mastrandrea, Lucy D ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Glycemic control; Inhalation; Insulin; Type 1 diabetes; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIGUANIDE; BIGUANIDE DERIVATIVE; GLUCOSE; INSULIN; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MEGLITINIDE; RECOMBINANT HUMAN INSULIN; STEROID; SULFONYLUREA;

CLINICAL TRIAL; CONTINUOUS INFUSION; COUGHING; DEVICE; DIABETES CONTROL; DIABETES MELLITUS; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN HYPOGLYCEMIA; INSULIN RELEASE; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN;

EID: 77950812405     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s6098     Document Type: Review

References (74)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. 2007. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008. URL. http://www.cdc.gov/diabetes/pubs/factsheet07.htm. Accessed August 26, 2009.
2. Bakker W, Eringa EC, Sipkema P, vanHinsbergh VW. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. 2009;335(1):165-189.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434-444.
4. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59(8):750-755.
5. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46(6):760-765.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
8. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46(3): 239-246.
9. Prentki M, Matschinsky FM. Ca2+, cAMP, and phospholipid-derived messengers in coupling mechanisms of insulin secretion. Physiol Rev. 1987;67(4):1185-1248.
10. Porte D, Sherwin R, Baron A. Ellenberg and Rifkin's Diabetes Mellitus. 6th ed. New York: McGraw-Hill. 2003:43-65.
11. ClincalTrials.gov. [homepage on the Internet]. A service of the US National Institutes of Health. [updated October 13, 2009]. URL: http:// clinicaltrials.gov/ct2/show/NCT00668850. Accessed October 14, 2009.
12. Logtenberg SJ, Kleefstra N, Houweling ST, et al. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes:a randomized controlled trial. Diabetes Care. 2009;32(8):1372-1377.
13. Laqueur E, Grevenstuk A. Uber die wirkunk intratrachealer zuführung von insulin. Klin Wochenschr. 1924;3:1273-1274.
14. Gänsslen M. Uber inhalation von insulin. Klin Wochenschr. 1925;4:71.
15. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
16. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med. 2005;172(12):1497-1504.
17. Katz IM, Schroeter JD, Martonen TB. Factors affecting the deposition of aerosolized insulin. Diabetes Technol Ther. 2001;3(3):387-397.
18. Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx system: physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther. 2000;2(2):185-197.
19. Bliss M. The Discovery of Insulin. Chicago, IL: University of Chicago Press; 1982.
20. Heubner W, de Jongh S, Laquer E. Uber inhalation von insulin. Klin Wochenschr. 1924;3:2342-2343.
21. Elliott RB, Edgar BW, Pilcher CC, Quested C, McMaster J. Parenteral absorption of insulin from the lung in diabetic children. Aust Paediatr J. 1987;23(5):293-297.
22. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43(12):781-801.
23. Rosenstock J, Bergenstal R, DeFronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31(11):2177-2182.
24. Rave K, Heise T, Pfutzner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled Technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007;30(9):2307-2308.
25. ClincalTrials.gov. [homepage on the Internet]. A service of the US National Institutes of Health. URL: www.ClinicalTrials.gov/ct2/results?term=inhaled+insulin. Accessed September 23, 2009.
26. Garg SK, Kelly WC. Insulin delivery via lungs - is it still possible? Diabetes Technol Ther. 2009;11(Suppl 2):S1-S3.
27. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28(5):1077-1082.
28. Rave K, Potocka E, Boss AH, Marino M, Costello D, Chen R. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11(7):715-720.
29. Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in Type 1 diabetic patients. Diabetologia. 2001;44(3):305-308.
30. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med. 2001;134(3):203-207.
31. Rave K, Nosek L, De la Pena A, et al. Dose response of inhaled dry- powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care. 2005;28:2400-2405.
32. de la Pena A, Seger M, Rave K, Heinemann L, Silverman B, Muchmore DB. AIR insulin capsules of different dose strengths may be combined to yield equivalent pharmacokinetics and glucodynamics. Diabetes Technol Ther. 2009;11(S2):S75-S79.
33. Royle P, Waugh L, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst. Rev. 2004;CD003890.
34. Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects. Diabetes Care. 2005;28(7):1630-1635.
35. Quattrin T, Belanger A, Bohannon NJV, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care. 2004;27(11):2622-2627.
36. Garg SK, Mathieu C, Rais N, et al. Two-year efficacy and safety of AIR inhaled insulin in patients with type 1 diabetes: An open-label randomized controlled trial. Diabetes Technol Ther. 2009;11(S2):S5-S16.
37. Bergenstal RM, Kapsner PL, Rendell MS, et al. Comparative efficacy and safety of AFRESA and a rapid-acting analog both given with glargine in subjects with T1DM in a 52-week study. Diabetes. 2009:A479.
38. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med. 2005;143(8):549-558.
39. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care. 2004;27(10):2356-2362.
40. Hermansen K, Rönnemaa T, Petersen AH, Bellaire S, Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system. Diabetes Care. 2004;27(1):162-167.
41. Rosenstock J, Eliaschewitz F, Heilmann C, Muchmore DB, Hayes R, Belin R. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. Diabetes Technol Ther. 2009;11(S2): S63-S73.
42. Rosenstock J, Capelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27(6):1318-1323.
43. Ford ES, Mokdad AH, Gregg EW. Trends in cigarette smoking among US adults with diabetes: findings from the Behavioral Risk Factor Surveillance System. Prev Med. 2004;39(6):1238-1242.
44. Wise S, Chien J, Yeo K, Richardson C. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabet Med. 2006;23(5):510-515.
45. Himmelmann A, Jendle J, Mellén A, Petersen AH, Dahl UL, Wolmer P. The impact of smoking on inhaled insulin. Diabetes Care. 2003;26(3): 677-682.
46. Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care. 2006;29(2):277-282.
47. Targher G, Alberiche M, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(11):3619-3624.
48. Fountaine R, Milton A, Checchio T, et al. Acute passive cigarette smoke exposure and inhaled human insulin (Exubera) pharmacokinetics. Br J Clin Pharmacol. 2008;65(6):864-870.
49. Kling J. Inhaled insulin's last gasp? Nat Biotech. 2008;26(5):479-480.
50. McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br J Clin Pharmacol. 2005;59(5):546-551.
51. Wolzt M, de la Pena A, Berclaz PY, Tibaldi FS, Gates JR, Muchmore DB. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, gluco- dynamics and pulmonary function in asthma. Diabetes Care. 2008;31(4): 735-740.
52. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and out- comes of diabetes, hypertension, and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962-969.
53. Rave K, de la Pena A, Tibaldi FS, et al. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease. Diabetes Care. 2007;30(7):1777-1782.
54. McGrath MW, Thomson ML. The effect of age, body size and lung volume change on alveolar-capillary permeability and diffusing capacity in man. J Physiol. 1959;146(3):572-582.
55. Henry RR, Mudalier S, Chu N, et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol. 2003;43(11):1228-1234.
56. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357(9253):331-335.
57. Barnett AH, Lange P, Dreyer M, Serdarevic-Pehar M. Long-term tolerability of inhaled human insulin (Exubera) in patients with poorly controlled type 2 diabetes. Int J Clin Pract. 2007;61(10):1614-1625.
58. Davis WA, Knuiman M, Kendal P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes. The Fremantle Diabetes Study. Diabetes Care. 2004;27(3):752-757.
59. Skyler JS. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy. Diabetes. 2004;53:A115.
60. Dahl-Jørgensen K, Torjesen P, Hanssen KF, Sandvik L, Aagenaes O. Increase in insulin antibodies during continuous subcutaneous insulin infusion and multiple-injection therapy in contrast to conventional treatment. Diabetes. 1987;36(1):1-5.
61. Lassmann-Vague V, Belicar P, Raccah D, Vialettes B, Sodoyez JC, Vague P. Immunogenicity of long-term intraperitoneal insulin adminstration with implantable programmable pumps: metabolic consequences. Diabetes Care. 1995;18(4):498-503.
62. Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 63. 1993;16(Suppl 3):155-165.
63. Walford S, Allison SP, Reeves WG. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia. 1982;22(2):106-110.
64. Peters A, Klose O, Hefty R, Keck F, Kerner W. The influence of insulin antibodies on the pharmacokinetics of NPH insulin in patients with type 1 diabetes treated with human insulin. Diabet Med. 1995;12(10):925-930.
65. Seewi O, Jaeger C, Bretzel RG, Schönau E. Insulin binding to antibodies is a risk factor for inexplicable severe hypoglycaemia in children with type-1 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116(5):293-297.
66. Kim MR, Sheeler LR, Mansharamani N, Haug MT, Faiman C, Gupta MK. Insulin antibodies and hypoglycemia in diabetic patients. Can a quantitiative analysis of antibody binding predict the risk of hypoglycemia? Endocrine. 1997;6(3):285-291.
67. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. J Clin Endocrinol Metab. 2005;90(6):3287-3294.
68. Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med. 1998;11(4):197-219.
69. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28(2):427-428.
70. Bergenstal R, Freemantle N, Leyk M, Cutler G, Hayes R, Muchmore DB. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes. Diabetes Technol Ther. 2009;11(S2): S45-S52.
71. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-496.
72. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-1310.
73. Cramer JA, Okikawa J, Bellaire S, Clauson P. Compliance with inhaled insulin treatment using the AERx iDMS insulin diabetes management system. Diabetes Technol Ther. 2004;6(6):800-807.
74. Black C, Cummins E, Royle P, Philip S, Waugh N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. Health Technol Assess. 2007;11(33):1-126.